Agence France-Presse

Watchmaker Genomics Launches TAPS+, Expanding Multimodal Capabilities in Oncology Ahead of AMP 2025

Watchmaker Genomics today announced the launch of TAPS+, a next-generation technology that unites genetic and epigenetic ...
Le Lézard

Illumina and Grail Veterans Launch Hepta With First Liquid Biopsy-Native AI That Detects Liver Disease With Tissue-Level Biological Insights

Hepta, a biotechnology company using transformer-based AI to read the cell-free DNA (cfDNA) epigenome and detect organ-specific signals of chronic disease, today emerged from stealth with $6.7 million ...

YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring

The test has been reported in peer‑reviewed journals such as Clinical Epigenetics and Biomolecules, and presented at major oncology conferences. EG BioMed’s CLIA and CAP accreditation enables U.S.
Le Lézard

Cardio Diagnostics Holdings, Inc. to Present Data Demonstrating PrecisionCHD's Ability to Detect INOCA and MINOCA at the American Heart Association Scientific Sessions

Cardio Diagnostics Holdings, Inc. , an AI-powered Precision Cardiovascular Medicine company, today announced that the Company will be presenting new data at the American Heart Association (AHA) ...